Wednesday, November 18, 2026

CJ OliveNetworks Builds Wise Medi AI Factory to Lead AX in Pharma Manufacturing

Input
2026-11-18 09:14:55
Updated
2026-11-18 09:14:55
Wise Medi's Second Plant. Courtesy of CJ OliveNetworks

[Financial News] CJ OliveNetworks is expanding its AX (AI transformation) business in pharmaceutical manufacturing by building AI factories.
CJ OliveNetworks announced on the 18th that it will build an AI factory serving as a leading AX model at Wise Medi's Second Plant in Jincheon County through the Support Project for Establishing a Win-Win AX Model. A subsidiary of Yuhan Corporation, Wise Medi is a company specializing in infusion solutions and was the first in Korea to develop and domestically produce 3-chamber bag nutritional infusion products.
Overseen by the Ministry of SMEs and Startups and led by CJ OliveNetworks, the project was established to strengthen the competitiveness of Korea's manufacturing industry. It focuses on providing CJ OliveNetworks' AX transition technologies and implementation experience to help small and midsize manufacturers with strong production capabilities accelerate AI- and data-driven manufacturing innovation.
CJ OliveNetworks will integrate AI and data technologies with Wise Medi's existing manufacturing infrastructure to make quality inspections and equipment management more intelligent, and implement an AX system tailored to the pharmaceutical industry that enhances the reliability and traceability of process and quality data.
Quality inspection is a key area for applying AI technology. AI vision inspection will be added to the existing inspection system to check the packaging of every infusion solution and identify products with uneven seals or folds. Inspection results will be linked to robots so that products deemed nonconforming are not loaded. The company plans to achieve AI detection performance of at least 95% to improve accuracy and consistency.
AI-based predictive maintenance will also be applied to equipment management to identify abnormal signs early and carry out proactive maintenance based on equipment condition. AI will analyze vibration data from major rotating equipment and provide on-site personnel with alerts and analysis results when an abnormal sign is detected. This will help personnel determine when maintenance is needed and what action to take, reducing unexpected equipment downtime and supporting stable production.
CJ OliveNetworks is incorporating into its AI factory the characteristics of the pharmaceutical industry, where strict quality control and data reliability are required.
In line with Good Manufacturing Practice (GMP) standards, key stages of quality testing will be connected with around 40 types of testing equipment to automatically collect and manage test data. ERP (Enterprise Resource Planning) and MES (Manufacturing Execution System) will also be integrated to link production and materials information with sterilization-process data, creating an environment in which production and quality histories can be traced by manufacturing lot. This will improve data reliability and enable the cause of any quality issues to be quickly identified and addressed.
Through this project, Wise Medi is expected to further improve production efficiency and quality reliability by adding AI technology to its existing manufacturing capabilities. The project is also expected to establish a manufacturing foundation that will enable the company to systematically meet global GMP requirements, including those for Data Integrity.
A Wise Medi representative said, “The Second Plant in Jincheon County was built with data-driven quality management in mind from the design stage. Through this project, we will add AI and data technologies to inspection, equipment management and test data management to further enhance the quality reliability of the infusion solutions supplied to patients.”
Song Won-cheol, who oversees Smart Logistics and Factory at CJ OliveNetworks, said, “This project is a leading example of applying AI and data technologies at a pharmaceutical manufacturing site where high levels of quality control and data reliability are required. Drawing on technologies validated on-site and our implementation experience, we will accelerate AX transformation in pharmaceutical manufacturing and support our customers in strengthening their manufacturing competitiveness.”

[email protected] Yeon Ji-an Reporter